- Home
- JUNS vs LUNG Comparison
JUNS vs LUNG Comparison
Compare JUNS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- LUNG
- Stock Information
- Founded
- JUNS 2015
- LUNG 1995
- Country
- JUNS United States
- LUNG United States
- Employees
- JUNS N/A
- LUNG N/A
- Industry
- JUNS
- LUNG Industrial Specialties
- Sector
- JUNS
- LUNG Health Care
- Exchange
- JUNS NYSE
- LUNG Nasdaq
- Market Cap
- JUNS 281.4M
- LUNG 256.3M
- IPO Year
- JUNS 2024
- LUNG 2020
- Fundamental
- Price
- JUNS $0.84
- LUNG $8.96
- Analyst Decision
- JUNS
- LUNG Buy
- Analyst Count
- JUNS 0
- LUNG 6
- Target Price
- JUNS N/A
- LUNG $11.92
- AVG Volume (30 Days)
- JUNS 602.5K
- LUNG 392.8K
- Earning Date
- JUNS 03-04-2025
- LUNG 02-19-2025
- Dividend Yield
- JUNS N/A
- LUNG N/A
- EPS Growth
- JUNS N/A
- LUNG N/A
- EPS
- JUNS N/A
- LUNG N/A
- Revenue
- JUNS N/A
- LUNG $83,789,000.00
- Revenue This Year
- JUNS N/A
- LUNG $22.26
- Revenue Next Year
- JUNS N/A
- LUNG $18.72
- P/E Ratio
- JUNS N/A
- LUNG N/A
- Revenue Growth
- JUNS N/A
- LUNG 22.01
- 52 Week Low
- JUNS $0.78
- LUNG $5.46
- 52 Week High
- JUNS $19.51
- LUNG $11.73
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- LUNG 75.17
- Support Level
- JUNS N/A
- LUNG $6.50
- Resistance Level
- JUNS N/A
- LUNG $9.37
- Average True Range (ATR)
- JUNS 0.00
- LUNG 0.54
- MACD
- JUNS 0.00
- LUNG 0.26
- Stochastic Oscillator
- JUNS 0.00
- LUNG 89.21
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.